Blood test to guide chemotherapy in stage II colon cancer
Part of Cancer, Digestive system clinical trials.
This trial is for people with stage II colon cancer who are not currently getting chemotherapy. It uses a blood test to look for tumor DNA, so doctors can decide if chemotherapy might help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage II colon cancer, confirmed by a biopsy or surgery.
- Your doctor has decided you do not need chemotherapy right now.
- You are healthy enough to receive a combination of two chemotherapy drugs (fluorouracil-like and oxaliplatin).
- You have not had another cancer in the last 5 years, except for treated skin cancer or very early stage cancer.
- You are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a blood test called ctDNA to decide whether you need extra (adjuvant) chemotherapy after stage II colon or certain stage II rectal cancer surgery. It may help avoid unnecessary treatment or better target people who still have signs of cancer after surgery.
This trial checks a blood test called circulating tumor DNA to help choose the best time and approach for chemotherapy after colon cancer surgery. It aims to reduce recurrence by identifying people who may benefit from treatment based on changes seen in the blood.
This trial studies a blood test (called ctDNA) in people with colon cancer that has spread to the liver and is being removed with curative surgery. The goal is to see how the blood test can help with planning and improving treatment after surgery.
This study uses a simple blood test to detect cancer DNA after surgery for early-stage colon cancer. The goal is to help doctors decide whether chemotherapy is truly needed based on the blood test results, rather than giving it to everyone.
This study tests whether giving additional (adjuvant) chemotherapy based on a special blood test—circulating tumor DNA (ctDNA)—can lower the risk of colon cancer coming back. It targets people with stage II–III colon cancer whose blood test is positive for minimal residual disease (MRD) after completing standard chemo.
This study uses a blood test to check for tumor DNA after surgery, which may help doctors decide if you need additional chemotherapy. It is for people with stage 3 colorectal cancer that is removed by surgery.
Hear when a new Circulating Tumor DNA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.